Literature DB >> 28107322

On-Body Injector: An Administration Device for Pegfilgrastim.

Linda J Mahler1, Regina DiBlasi1, Anielka Perez1, Jeannie Gaspard1, Dayna McCauley1.   

Abstract

Many chemotherapy regimens used today require the support of a granulocyte-colony-stimulating factor for the prevention of life-threatening neutropenia. In March 2015, a delivery method was introduced for Neulasta® (pegfilgrastim) through an on-body injector (Onpro®), which may eliminate the need for patients to return for injection after chemotherapy, increase workflow, and allow more patients to be seen. The purpose of this study was to monitor the implementation of the Onpro delivery system in an outpatient facility.

Entities:  

Keywords:  febrile neutropenia; on-body injector; patient satisfaction; pegfilgrastim

Mesh：

Substances：

Year:  2017        PMID： 28107322     DOI： 10.1188/17.CJON.121-122

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN： 1092-1095            Impact factor:   1.027


  4 in total

Review 1.  Development of Delivery Systems for Local Administration of Cytokines/Cytokine Gene-Directed Therapeutics: Modern Oncologic Implications.

Authors:  Jhalak Dholakia; Alexander C Cohen; Charles A Leath; Elizabeth T Evans; Ronald D Alvarez; Premal H Thaker
Journal:  Curr Oncol Rep       Date:  2022-02-10       Impact factor: 5.075

2.  Initial testing of pegfilgrastim (Neulasta Onpro) on-body injector in multiple radiological imaging environments.

Authors:  Zaiyang Long; Anil Nicholas Kurup; Nicole M Jensen; Nicholas J Hangiandreou; Beth A Schueler; Lifeng Yu; Shuai Leng; Christopher P Wood; Joel P Felmlee
Journal:  J Appl Clin Med Phys       Date:  2021-01-04       Impact factor: 2.102

Review 3.  Pegfilgrastim Biosimilars in US Supportive Oncology: A Narrative Review of Administration Options and Economic Considerations to Maximize Patient Benefit.

Authors:  Sophia Z Humphreys; Robert B Geller; Paul Walden
Journal:  Oncol Ther       Date:  2022-09-16

4.  Retrospective Analysis of Clinical Outcomes Associated With the Use of Pegfilgrastim On-body Injector in Patients Receiving Chemotherapy Requiring Granulocyte Colony-Stimulating Factor Support.

Authors:  Jolly Patel; Rebecca Ann Rainess; Miranda J Benfield; Kate M L Rogers; Donald C Moore; Chris Larck; Justin R Arnall
Journal:  Hosp Pharm       Date:  2019-08-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.